newsfilter
← Latest News
Business Wire·

TYME Technologies, Inc. Announces Oral SM-88 Poster Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

-- Oral SM-88 is an investigational cancer metabolism-based therapy that has demonstrated clinical responses across 15 different types of solid tumors and hematologic cancers – -- Prestigious conference features new, innovative findings in gastroin